Combination immunotherapy induces distinct T-cell repertoire responses when administered to patients with different malignancies

Abstract

BackgroundCTLA-4 blockade with ipilimumab is Food and Drug Administration-approved for melanoma as a monotherapy and has been shown to modulate the circulating T-cell repertoire. We have previously reported clinical trials...